IDEAYA Biosciences (NASDAQ:IDYA) Given New $35.00 Price Target at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group raised its price target on IDEAYA to $35 from $31 while maintaining a "neutral" rating, implying about a 9.72% upside from the prior close.
• Multiple firms upgraded targets sharply — Wells Fargo $48 (overweight), Wedbush $58 (outperform), Citigroup $65 (buy) — leaving a MarketBeat consensus of "Moderate Buy" and a consensus price target of $50.44.
• Positive OptimUM‑02 topline results showed a meaningful improvement in median progression‑free survival (6.9 vs 3.1 months, HR 0.42), fueling analyst/media attention and insider buying (director purchased 50,000 shares), though analysts warn regulatory, safety, and commercial risks remain.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) had its price objective boosted by equities researchers at The Goldman Sachs Group from $31.00 to $35.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. The Goldman Sachs Group's price target suggests a potential upside of 9.72% from the stock's previous close.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of IDEAYA Biosciences from a "buy" rating to a "sell" rating in a research report on Saturday, February 21st. Wells Fargo & Company upped their target price on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an "overweight" rating in a research report on Tuesday. Wedbush boosted their price target on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the company an "outperform" rating in a report on Tuesday. Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Finally, Citigroup boosted their price target on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, February 19th. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $50.44.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock traded down $0.92 on Tuesday, hitting $31.90. 1,571,574 shares of the company's stock traded hands, compared to its average volume of 1,083,885. The firm's 50-day moving average price is $32.41 and its two-hundred day moving average price is $32.58. The stock has a market capitalization of $2.80 billion, a PE ratio of -24.56 and a beta of 0.02. IDEAYA Biosciences has a one year low of $15.84 and a one year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The business had revenue of $10.88 million for the quarter, compared to the consensus estimate of $5.95 million. The business's revenue was up 55.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.49) EPS. On average, analysts forecast that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey Stein purchased 50,000 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the acquisition, the director directly owned 54,281 shares of the company's stock, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On IDEAYA Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. boosted its stake in IDEAYA Biosciences by 1,071.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 3,795 shares of the company's stock worth $131,000 after purchasing an additional 3,471 shares during the period. Flax Pond Capital LLC acquired a new position in IDEAYA Biosciences in the 4th quarter worth $1,353,000. Invesco Ltd. boosted its stake in IDEAYA Biosciences by 91.9% in the 4th quarter. Invesco Ltd. now owns 238,314 shares of the company's stock worth $8,239,000 after purchasing an additional 114,118 shares during the period. XTX Topco Ltd acquired a new position in IDEAYA Biosciences in the 4th quarter worth $2,288,000. Finally, Virtus Investment Advisers LLC boosted its stake in IDEAYA Biosciences by 53.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 7,819 shares of the company's stock worth $270,000 after purchasing an additional 2,712 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

IDEAYA Biosciences News Roundup

Here are the key news stories impacting IDEAYA Biosciences this week:

• Positive Sentiment: OptimUM‑02 reported a statistically significant improvement in median progression‑free survival (BICR): 6.9 months for the darovasertib combination vs 3.1 months for investigational control (HR 0.42), meeting the trial's primary endpoint — a clear clinical readout that supports potential regulatory filings and commercial opportunity in a high‑unmet‑need indication. IDEAYA and Servier announce positive topline results (PR Newswire)
• Positive Sentiment: Wide media coverage highlights the trial success and investor enthusiasm (reports of share moves and analyst attention), amplifying sentiment and trading volume following the announcement. Ideaya stock jumps on eye cancer trial results (Barron's)
• Positive Sentiment: Wedbush raised its price target to $58 and kept an "outperform" rating — the highest of the three published raises — implying meaningful upside vs. the current price and signaling increased sell‑side conviction. Wedbush raises price target to $58 (The Fly)Coverage summary (Benzinga)
• Positive Sentiment: Guggenheim raised its target to $54 and reiterated a "buy" rating, adding institutional validation of the trial data's commercial implications. Guggenheim raises target to $54 (Benzinga)
• Positive Sentiment: Wells Fargo raised its target to $48 and moved to "overweight," reflecting broader analyst upgrades that can support continued bullish momentum and higher targets in the near term. Wells Fargo raises target to $48 (Benzinga)
• Neutral Sentiment: Company filed detailed topline results and management provided transcripts/slides for investors; these materials help analysts refine models but require regulatory and safety review to translate into approvals. OptimUM‑02 topline results slides/transcript (Seeking Alpha)
• Negative Sentiment: Analysts and commentators caution that regulatory approval and commercial rollout are not guaranteed — uveal melanoma is a small, specialized market and further safety, regulatory review, and payer acceptance remain risks that could limit upside. Approval not a formality — analysis (Seeking Alpha)

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.